Major Breakthrough in Precision Medicine: Personalized Diagnosis and Treatment Forum Successfully Concludes

On the journey of modern medicine, personalized diagnosis and treatment are gradually becoming a core strategy for improving therapeutic outcomes and optimizing patient experience. With a deepening understanding of the molecular mechanisms of diseases and breakthroughs in biotechnological fields such as genomics and proteomics, personalized diagnosis and treatment have transitioned from concept to clinical practice, offering patients more precise treatment regimens. Furthermore, policy support, heightened public health awareness, and active participation from the capital market have created a favorable environment for the innovation and development of personalized diagnosis and treatment.

On the morning of May 8, 2024, the “Personalized Diagnosis and Treatment Forum,” co-hosted by VCBeat and VB100, was grandly held at the Beijing·Beiren Yichuang International Exhibition Center. Moderated by Deng Jianliang, Partner at Tianhui Capital, the forum brought together experts, scholars, and industry leaders from diverse fields, including scientific research, clinical practice, and enterprise. As a premier event in the healthcare sector, the Personalized Diagnosis and Treatment Forum provided a platform for exchange and collaboration, fostering in-depth discussions on the latest advancements, technical challenges, and future opportunities in personalized diagnosis and treatment, thereby promoting innovation and application in this field.

Deng Jianliang | Partner, Tianhui Capital

Advances in Mass Spectrometry Technology and the Future of Precision Medicine

 Ouyang Zheng | Dean of Tsinghua Shenzhen International Graduate School, Professor in the Department of Precision Instruments at Tsinghua University, Founder of Qingpu Technology

Ouyang Zheng, Dean of the Shenzhen International Graduate School of Tsinghua University, Professor in the Department of Precision Instruments at Tsinghua University, and Founder of Clear Spectrum Technology, pointed out that mass spectrometry faces several challenges in clinical applications, including the complexity of sample pretreatment, high instrument prices, and substantial operational and maintenance costs. To address these issues, Clear Spectrum Technology is dedicated to simplifying and intelligentizing miniaturized mass spectrometry technology, making it easier to operate and maintain, while reducing both usage and acquisition costs, thereby promoting the translation of mass spectrometry into clinical practice. Ouyang Zheng illustrated the application of compact mass spectrometers in point-of-care testing, such as rapid diagnosis during glioma surgery and bedside monitoring of antibiotic drug concentrations in intensive care units (ICUs), demonstrating the potential and importance of mass spectrometry in precision medicine. Finally, Ouyang Zheng provided an outlook on the future development of mass spectrometry, noting that its applications in the healthcare sector will become increasingly widespread, particularly in the realms of precision medicine and personalized therapy.

Latest Generation of Independently Developed Gene Sequencing Systems and Comprehensive Solutions

Wang Daqian | Co-founder and CEO of Puyi Biotech

Puyi BioCo-founder,CEOWang DaThousandThis article begins by introducing the background of the gene sequencing industry, highlighting the rapid growth in the global market size of gene sequencers and consumables, as well as China’s market potential in this field. Nanopore sequencing technology holds a significant position in RNA research, particularly in studies exploring the association between non-coding RNAs and diseases. As the only technology capable of direct RNA sequencing, nanopore sequencing will play a pivotal role. Puyi Bio, a company specializing in nanopore sequencing technology, has developed its technological achievements through the commercialization of scientific outcomes from the Institute of Biophysics, Chinese Academy of Sciences. Puyi Bio’s sequencing platform offers a one-stop solution characterized by speed, accuracy, and long read lengths, making it suitable for diverse research and clinical application scenarios.

From Macro to Micro: Innovation and Application of Diagnostic and Therapeutic Technologies for Gut Microecology

Kailun Lu | Founder and Chairman of Leyi Bio

Lu Kelun, Founder and Chairman of Leyi BioThis article provides an in-depth introduction to the integrated clinical diagnosis and treatment solution for gut microecology, particularly highlighting its role in the onset and progression of digestive system diseases. It emphasizes the potential of gut microbiota in the early and ultra-early diagnosis of functional gastrointestinal disorders (FGIDs). Small intestinal bacterial overgrowth (SIBO), a typical example of gut microecological imbalance, is associated with gastrointestinal and even systemic diseases. Leyi Bio has achieved a first-mover technological innovation advantage in the field of breath molecular diagnostics. By detecting hydrogen and methane in human exhaled breath, it enables non-invasive, convenient, and precise diagnosis of SIBO and other functional gastrointestinal disorders. Its independently developed methane and hydrogen breath testing device is the first in China to adopt the “gold standard” methodology and integrate big data algorithms specific to the Chinese population, offering leading advantages in cost, operability, and accuracy.

MRD Ushers in a New Era of Oncology Treatment

Wang Haibo | Vice President of Technology and Strategic Cooperation Operations, Zhenhe Technology

Wang Haibo, Vice President of Strategic Cooperation and Operations at Zhenhe TechnologyThis article introduces the personalized needs of tumor treatment, emphasizes the critical role of genetic biomarkers in targeted drug therapy, and elaborates on the concept and clinical value of minimal residual disease (MRD) testing. By analyzing circulating tumor DNA (ctDNA) in plasma, MRD testing can detect minute residual tumor cells with high sensitivity, which plays a significant role in predicting tumor recurrence and guiding subsequent treatment. The author also discusses the role of MRD testing in clinical treatment decision-making, including prognostic assessment, recurrence monitoring, efficacy prediction, and companion diagnostics. Multiple studies are cited to confirm the substantial value of MRD testing in predicting tumor recurrence, guiding adjuvant therapy, and informing personalized treatment strategies. Genetron Health has developed MRD testing products based on next-generation sequencing (NGS) technology and is exploring collaborations with pharmaceutical companies and hospitals to achieve widespread clinical application of MRD testing.

AI-Empowered Disease-Specific Databases: Promoting Standardized Diagnosis and Treatment and Long-Term Management of Patients with Respiratory Diseases

 Shen Ye | Founder and CEO of Langye Medical

Founder of Langye Medical andCEOShen YeIt was noted that there are approximately 60 million asthma patients in China. Although patients with severe asthma constitute a minority, they consume the vast majority of healthcare resources dedicated to asthma care. He emphasized the role of eosinophils in the pathogenesis of asthma and their significance as a key factor in assessing patient prognosis. He proposed that to improve disease control among asthma patients, it is essential to establish actionable screening and triage criteria, diagnostic and treatment protocols, and management pathways. He shared Longye Medical’s progress in constructing diagnostic and treatment pathways for severe asthma, highlighting the importance of dynamic correlation analysis and database development, as well as leveraging artificial intelligence (AI) technologies to enhance the efficiency of healthcare professionals. Through data-driven solutions, physicians can complete their daily tasks more rapidly, systematically, and intelligently. Furthermore, Longye Medical focuses on improving patients’ diagnostic and treatment experiences by providing services such as early warnings and AI assistants through an integrated mobile support system both within and outside hospital settings.

Development of Gut Microbiota-Based Disease Classification Models and Clinical Application of Fecal Microbiota Transplantation Therapy

Yingying Wang | Senior Product Manager, Shanghai Ruie Biotech

Shanghai Ruiyi BiotechPerson in ChargeThe presentation first emphasized the importance of the gut microbiome, noting that gut flora is associated with the onset and progression of 90% of human diseases, thereby earning it the title of the body’s “second genome.” She highlighted that dysbiosis of the gut microbiota is linked to various chronic conditions, such as diabetes, hypertension, constipation, and diarrhea. Theoretically, modulating the gut microecology can achieve disease prevention and treatment without side effects. Regarding therapeutic approaches, traditional methods for regulating gut microecology were introduced, including dietary therapy and supplementation with probiotics and prebiotics, while also pointing out the potential of fecal microbiota transplantation (FMT) in clinical treatment. Finally, she underscored the importance of establishing industry standards for FMT, encompassing rigorous traceability systems, donor screening criteria, and quality control frameworks. Shanghai Ruie Biotechnology has achieved numerous research outcomes in the field of gut microbiome studies, including the development of testing services, disease risk assessment models, and collaborative clinical application projects on FMT with Shanghai Tenth People’s Hospital.

Domestic Gene Sequencing Platforms Facilitate Personalized Diagnosis and Treatment

Lin Wei | Marketing Director, Genetron Health

Lin Wei, Marketing Director at Genetron HealthThe presentation highlighted Genetron Health’s advantages in the independent production of core raw materials and instruments, including the in-house research, development, and manufacturing of sequencers, sequencing chips, and sequencing reagents. He noted that the company boasts hardware systems with high sensitivity and high resolution, along with precise and rapid base-calling algorithms, ensuring the accuracy of sequencing results. Genetron Health’s SURFSeq5000 high-throughput gene sequencing platform is leading the global development of sequencing technology through its accuracy, speed, high throughput, and cost-effectiveness. It demonstrates superior performance in tumor genome targeted sequencing and whole-genome methylation sequencing, offering capabilities comparable to imported equipment and even surpassing international brands in certain areas, such as methylation sequencing. Finally, Lin Wei summarized Genetron Health’s mission, “Making Life Readable, Making Health Shapable,” and invited attendees to follow Genetron Health for more information on new products and performance enhancements in personalized diagnosis and treatment.